UPD: Recombinant Proteins and Peptides Manufacturers

Enzene Upstream Process Development (UPD) team has extensive experience in the development, characterization, and scale-up of a wide range of therapeutic proteins. These include recombinant monoclonal antibodies, antibody fragments, and fusion proteins based on microbial and mammalian platforms. We are committed to developing continuous bioprocesses for mammalian cell-based products using perfusion technology.

Capabilities

Process & Product development initiatives are built to exacting standards of safety, yield, and cost-effectiveness.
Development of bench-scale and scale-up of fed-batch and perfusion processes for recombinant proteins from microbial and mammalian systems.
Platform processes for a variety of mammalian and microbial expression systems.
Scale down fed-batch and perfusion models.
Bench scale process characterization.
Continuous bioprocessing using perfusion systems with connection to continuous purification.
DoE based approach for process development.
Scale-up of processes up to 50L
Evaluation of the techno-economic viability of the processes

Infrastructure

We use the latest equipment in our facility to achieve the high degree of accuracy and quality needed, supported by world-class infrastructures, such as

Advanced high throughput system (Ambr250) for clone evaluation, process development, and characterization.
Cell retention devices (ATF2 and ATF4).
Fully automated fermenter/bioreactor systems from 1L to 50L scale.